A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus

Treatment Naïve ◽

A cost-effectiveness analysis of shortened direct-acting antiviral treatment for mild chronic hepatitis C virus

Journal of Hepatology ◽

10.1016/s0168-8278(18)31333-3 ◽

2018 ◽

Vol 68 ◽

pp. S539

Author(s):

C. Fawsitt ◽

P. Vickerman ◽

G. Cooke ◽

N.J. Welton

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Antiviral Treatment ◽

Direct Acting Antiviral ◽

Effectiveness Analysis ◽

A Cost-Effectiveness Analysis Of Shortened Direct-Acting Antiviral Treatment For Mild Chronic Hepatitis C Virus

Value in Health ◽

10.1016/j.jval.2017.08.2309 ◽

2017 ◽

Vol 20 (9) ◽

pp. A788

Author(s):

CG Fawsitt ◽

P Vickerman ◽

G Cooke ◽

NJ Welton

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Antiviral Treatment ◽

Direct Acting Antiviral ◽

Effectiveness Analysis ◽

Cost-effectiveness of direct-acting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatment-naïve and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in Japan

Journal of Medical Economics ◽

10.1080/13696998.2016.1206908 ◽

2016 ◽

Vol 19 (12) ◽

pp. 1144-1156 ◽

Cited By ~ 10

Author(s):

Suchin Virabhak ◽

Kikuo Yasui ◽

Kiyotaka Yamazaki ◽

Scott Johnson ◽

Dominic Mitchell ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Virus Genotype ◽

Direct Acting Antiviral ◽

Treatment Naïve ◽

Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Outcome in Genotype 1 Noncirrhotic Treatment-Naïve Patients With Chronic Hepatitis C Virus

Value in Health ◽

10.1016/j.jval.2019.08.012 ◽

2020 ◽

Vol 23 (2) ◽

pp. 180-190 ◽

Cited By ~ 1

Author(s):

Christopher G. Fawsitt ◽

Peter Vickerman ◽

Graham S. Cooke ◽

Nicky J. Welton ◽

Eleanor Barnes ◽

...

Keyword(s):

Chronic Hepatitis ◽

Treatment Outcome ◽

Hepatitis C Virus ◽

Cost Effectiveness ◽

Hepatitis C ◽

Genotype 1 ◽

Effectiveness Analysis ◽

Treatment Naïve ◽

Baseline Testing

Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimise Treatment Duration in Genotype 1 Non-Cirrhotic Treatment-Naïve Patients with Chronic Hepatitis C Virus

Value in Health ◽

10.1016/j.jval.2018.04.043 ◽

2018 ◽

Vol 21 ◽

pp. S9

Author(s):

CG Fawsitt ◽

P Vickerman ◽

G Cooke ◽

NJ Welton

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Cost Effectiveness ◽

Hepatitis C ◽

Treatment Duration ◽

Genotype 1 ◽

Effectiveness Analysis ◽

Treatment Naïve ◽

Baseline Testing

Cost-effectiveness analysis of baseline testing for resistance-associated polymorphisms to optimise treatment duration in genotype 1 non-cirrhotic treatment-naive patients with chronic hepatitis C virus

Journal of Hepatology ◽

10.1016/s0168-8278(18)30820-1 ◽

2018 ◽

Vol 68 ◽

pp. S300-S301

Author(s):

C. Fawsitt ◽

P. Vickerman ◽

G. Cooke ◽

N.J. Welton

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Cost Effectiveness ◽

Hepatitis C ◽

Treatment Duration ◽

Genotype 1 ◽

Effectiveness Analysis ◽

Treatment Naïve ◽

Baseline Testing

MAGELLAN-1, Part 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic hepatitis C virus genotype 1 or 4 and prior direct-acting antiviral treatment failure

Journal of Hepatology ◽

10.1016/s0168-8278(17)30432-4 ◽

2017 ◽

Vol 66 (1) ◽

pp. S83-S84 ◽

Cited By ~ 14

Author(s):

F. Poordad ◽

S. Pol ◽

A. Asatryan ◽

M. Buti ◽

D. Shaw ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Treatment Failure ◽

Antiviral Treatment ◽

Genotype 1 ◽

Virus Genotype ◽

Direct Acting Antiviral ◽

DIRECT ACTING ANTIVIRAL TREATMENT FOR CHRONIC HEPATITIS C VIRUS INFECTION. REAL WORLD EXPERIENCE IN AN IRISH PAEDIATRIC COHORT

10.26226/morressier.5ad774dcd462b80296ca674b ◽

2018 ◽

Author(s):

Karina Butler

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Virus Infection ◽

Antiviral Treatment ◽

Hepatitis C Virus Infection ◽

Direct Acting Antiviral ◽

Paediatric Cohort ◽

Management of treatment-naïve chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options

Journal of Viral Hepatitis ◽

10.1111/jvh.12278 ◽

2014 ◽

Vol 22 (2) ◽

pp. 175-183 ◽

Cited By ~ 14

Author(s):

P. A. Cortesi ◽

A. Ciaccio ◽

M. Rota ◽

J. K. Lim ◽

S. De Salvia ◽

...

Keyword(s):

Chronic Hepatitis ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Treatment Options ◽

Cost Effectiveness Analysis ◽

Genotype 1 ◽

Effectiveness Analysis ◽

Treatment Naïve

Cost–Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong

Digestive Diseases and Sciences ◽

10.1007/s10620-020-06281-8 ◽

2020 ◽

Cited By ~ 1

Author(s):

Man-Fung Yuen ◽

Sze-Hang Liu ◽

Wai-Kay Seto ◽

Lung-Yi Mak ◽

Shelby L. Corman ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hong Kong ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Cost Utility ◽

Genotype 1 ◽

Direct Acting Antiviral ◽